Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06738745

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

A Phase II Study of HRS-2189 Combined HRS-5041 in Metastatic Prostate Cancer

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
Fudan University · Academic / Other
Sex
Male
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Our study is aimed to evaluate the efficacy and safety of HRS-2189 combined with HRS-5041 in metastatic prostate cancer.

Conditions

Interventions

TypeNameDescription
DRUGHRS-2189HRS-2189
DRUGHRS-5041HRS-5041

Timeline

Start date
2024-12-31
Primary completion
2027-01-31
Completion
2027-08-31
First posted
2024-12-18
Last updated
2024-12-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06738745. Inclusion in this directory is not an endorsement.

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer (NCT06738745) · Clinical Trials Directory